APVO · Insider Trading
Aptevo Therapeutics Inc
Every open-market purchase and sale reported by APVO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Dirk Huebner | SVP, CMO | MIXED | +482 | −$635 |
| 2026-08-10 | Marvin L White | Executive Chair | MIXED | +1,261 | −$1.65K |
| 2026-08-10 | Barbara Lopez Kunz | Director | M | +400 | — |
| 2026-08-10 | John Niederhuber | Director | M | +400 | — |
| 2026-08-10 | Zsolt Harsanyi | Director | M | +400 | — |
| 2026-08-10 | Jeffrey G. Lamothe | President and CEO | M | +961 | — |
| 2026-08-10 | Grady Grant III | Director | M | +400 | — |
| 2026-08-10 | Daphne Taylor | SVP, CFO | M | +638 | — |
| 2026-08-10 | Daniel Abdun-Nabi | Director | M | +400 | — |
| 2026-08-10 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | M | +638 | — |
| 2025-11-12 | Grady Grant III | Director | Buy | +13,513 | +$20.13K |
| 2025-08-08 | John Niederhuber | Director | A | +7,200 deriv. | — |
| 2025-08-08 | Marvin L White | President and CEO | A | +30,000 deriv. | — |
| 2025-08-08 | Jeffrey G. Lamothe | EVP, COO | A | +17,300 deriv. | — |
| 2025-08-08 | Zsolt Harsanyi | Director | A | +7,200 deriv. | — |
| 2025-08-08 | Grady Grant III | Director | A | +7,200 deriv. | — |
| 2025-08-08 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | A | +11,500 deriv. | — |
| 2025-08-08 | Daniel Abdun-Nabi | Director | A | +7,200 deriv. | — |
| 2025-08-08 | Barbara Lopez Kunz | Director | A | +7,200 deriv. | — |
| 2025-08-08 | Daphne Taylor | SVP, CFO | A | +11,500 deriv. | — |
| 2025-08-08 | Dirk Huebner | SVP, CMO | A | +11,500 deriv. | — |
| 2025-07-21 | John Niederhuber | Director | M | +1 | — |
| 2025-07-21 | Daphne Taylor | SVP, CFO | M | +3 | — |
| 2025-07-21 | Zsolt Harsanyi | Director | M | +1 | — |
| 2025-07-21 | Grady Grant III | Director | M | +1 | — |
| 2025-07-21 | Marvin L White | President and CEO | M | +10 | — |
| 2025-07-21 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | M | +3 | — |
| 2025-07-21 | Daniel Abdun-Nabi | Director | M | +1 | — |
| 2025-07-21 | Jeffrey G. Lamothe | EVP, COO | M | +5 | — |
| 2025-07-21 | Barbara Lopez Kunz | Director | M | +1 | — |
| 2025-03-04 | Jeffrey G. Lamothe | EVP, COO | M | +5 | — |
| 2025-03-04 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | M | +4 | — |
| 2025-03-04 | Daphne Taylor | SVP, CFO | M | +3 | — |
| 2025-03-04 | Marvin L White | President and CEO | M | +14 | — |
| 2024-08-09 | Daphne Taylor | SVP, CFO | M | +158 | — |
| 2024-08-09 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | M | +213 | — |
| 2024-08-09 | Jeffrey G. Lamothe | EVP, COO | M | +314 | — |
| 2024-07-19 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | A | +8,550 deriv. | — |
| 2024-07-19 | Jeffrey G. Lamothe | EVP, COO | A | +12,825 deriv. | — |
| 2024-07-19 | Zsolt Harsanyi | Director | A | +925 deriv. | — |
| 2024-07-19 | Marvin L White | President and CEO | A | +22,325 deriv. | — |
| 2024-07-19 | John Niederhuber | Director | A | +925 deriv. | — |
| 2024-07-19 | Grady Grant III | Director | A | +925 deriv. | — |
| 2024-07-19 | Daniel Abdun-Nabi | Director | A | +925 deriv. | — |
| 2024-07-19 | Barbara Lopez Kunz | Director | A | +925 deriv. | — |
| 2024-07-19 | Daphne Taylor | SVP, CFO | A | +8,550 deriv. | — |
| 2024-06-03 | SoYoung Kwon | SVP, GC, BD & Corp Affairs | M | +42 | — |
| 2024-06-03 | Barbara Lopez Kunz | Director | M | +88 | — |
| 2024-06-03 | Grady Grant III | Director | M | +88 | — |
| 2024-06-03 | Daniel Abdun-Nabi | Director | M | +88 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Marvin L White | Executive Chair | 1,667 | $2.57K |
| Grady Grant III | Director | 1,150 | $1.77K |
| Jeffrey G. Lamothe | President and CEO | 961 | $1.48K |
| Daphne Taylor | SVP, CFO | 638 | $983 |
| Dirk Huebner | SVP, CMO | 638 | $983 |
| SoYoung Kwon | SVP, GC, BD & Corp Affairs | 638 | $983 |
| Zsolt Harsanyi | Director | 400 | $616 |
| Daniel Abdun-Nabi | Director | 400 | $616 |
| John Niederhuber | Director | 400 | $616 |
| Barbara Lopez Kunz | Director | 400 | $616 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APVO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.